Brief: ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data
13/09/2024 23:19
Sept 14 (Reuters) - ESSA Pharma Inc EPIX.O :
* ESSA PHARMA PRESENTS UPDATED PHASE 1/2 MASOFANITEN
(EPI-7386)
CLINICAL DATA AT THE 2024 ESMO CONGRESS
* ESSA PHARMA - COMBINATION OF MASOFANITEN PLUS ENZALUTAMIDE
CONTINUES TO BE WELL TOLERATED WITH DURABLE REDUCTIONS IN PSA IN
PATIENTS WITH MCRPC
Source text for Eikon: ID:nCNWT6DZpa
Further company coverage: EPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ESSA Pharma
See all newsBrief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: ESSA Pharma Provides Update On Its Application To The Supreme Court Of British Columbia For Amended Interim Order
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics